SC 13G/A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

SC 13G - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

GAITHERSBURG, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2024. Shuttle Pharma's recent highlights include the following: Successfully dosed first three patients in the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with brain tumors (glioblastoma). Ropidoxuridine is Shuttle Pharma's lead

GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the pricing of its "reasonable best efforts" public offering with a health-care focused institutional investor for the purchase and sale of up to 2,950,820 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,950,820 shares of common stock at a combined offering price of $1.525 per share and accompanying warrant, priced at-the-market under

GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that, during the third quarter of this year, it paid off the entirety of the outstanding balance due under its Senior Secured Convertible Note ("Note") issued on January 11, 2023. The initial balance of the Note was $4.3 million and was originally repayable over a 26-month period ending March 11, 2025. During the term of the note, Shuttle Pharma made periodic cash payments totaling $1.3 million

GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today that the first three patients in its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patients with glioblastoma have been successfully dosed. Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure. Shuttle has received Orphan Drug Designation

GAITHERSBURG, Md., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has finalized agreements with all six of the planned site enrollment locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma following the entry into agreements with Georgetown University Medical Center and UNC Medical Center. The Company previously entered agreements with UVA Cancer Center, John Theurer Cancer Center at Hackensack Univ

GAITHERSBURG, Md., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy ("RT"), today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will present at the ThinkEquity Conference on October 30, 2024 at 8:30 am ET. The Company will also host in person one-on-one meetings with investors. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies. Dr. Dritschilo's presentati

GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has entered into agreements with two additional site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Four of the planned six trial sites are now prepared to enroll patients in the clinical trial, including the UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, Allegheny Health Network (AHN)

GAITHERSBURG, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the issuance of U.S. Patent No. 12,077,515, titled "Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease." This patent was officially issued on September 3, 2024, further strengthening Shuttle Pharma's intellectual property portfolio and supporting its ongoing efforts to develop novel therapeutics targeting histone deacetylase (HDAC) enzymes. The newly issued patent covers a series of selective HDAC inhibitors designed to

GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2024. Shuttle Pharma's recent highlights include the following: Enrollment of patients in the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma has recently opened following the entry of agreements with two site locations to administer t

GAITHERSBURG, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Rule. Nasdaq sent notice to the Company that it had regained compliance as of August 27, 2024, after it traded above $1.00 per share for ten consecutive trading days. About Shuttle Pharmaceuticals Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma

8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

10-Q - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

424B4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

EFFECT - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

D - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript reporting on the ability of one of the Company's HDAC inhibitor pre-clinical assets, SP-1-303, which exhibits ataxia-telangiectasia mutated protein (ATM) activation and modulation of estrogen receptor expression resulting in substantial growth inhibition of estrogen receptor positive breast cancer cells (ER + BC). The published manuscript, titled "Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, prefere

Gainers Reshape Lifesciences (NASDAQ:RSLS) shares rose 88.9% to $0.39 during Tuesday's after-market session. The market value of their outstanding shares is at $9.2 million. Dermata Therapeutics (NASDAQ:DRMA) stock rose 12.8% to $3.7. The company's market cap stands at $1.6 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) stock moved upwards by 7.88% to $0.47. The company's market cap stands at $7.8 million. Ocular Therapeutix (NASDAQ:OCUL) shares rose 7.25% to $6.36. The market value of their outstanding shares is at $985.0 million. Unicycive Therapeutics (NASDAQ:UNCY) shares rose 6.02% to $0.89. The company's market cap stands at $33.4 million. Virios Therapeutics (NASDAQ:VIRI) shares

Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(0.10) per share. This is a 42.86 percent decrease over losses of $(0.07) per share from the same period last year.

Shares of Macatawa Bank Corporation (NASDAQ:MCBC) rose sharply in today’s pre-market trading after Wintrust Financial Corporation (NASDAQ:WFTC) and Macatawa Bank announced that they have entered into a definitive merger agreement for Wintrust to acquire Macatawa in an all-stock transaction. Macatawa Bank shares jumped 37% to $13.60 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Dynatronics Corporation (NASDAQ:DYNT) shares rose 69.8% to $0.6301 in pre-market trading after dipping over 5% on Monday. Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) gained 55% to $0.6974 in pre-market trading after the company posted a profit for the fourth quarter.

Gainers Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 33.9% to $0.83 during Friday's after-market session. The market value of their outstanding shares is at $3.2 million. Masimo (NASDAQ:MASI) shares rose 12.48% to $151.77. The company's market cap stands at $8.0 billion. Vicarious Surgical (NYSE:RBOT) shares moved upwards by 11.17% to $0.38. The market value of their outstanding shares is at $66.7 million. Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 11.11% to $2.2. The company's market cap stands at $8.0 million. Psyence Biomedical (NASDAQ:PBM) stock increased by 9.09% to $1.2. The company's market cap stands at $16.0 million. Bright Green (NASDAQ:BGXX) shares ro

Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(0.11) per share. This is a 83.33 percent decrease over losses of $(0.06) per share from the same period last year.

https://register.epo.org/application?number=EP19738394

Gainers Inspire Veterinary (NASDAQ:IVP) stock moved upwards by 37.5% to $0.26 during Thursday's after-market session. The market value of their outstanding shares is at $2.8 million. Tharimmune (NASDAQ:THAR) stock rose 16.5% to $0.53. The market value of their outstanding shares is at $1.3 million. MyMD Pharmaceuticals (NASDAQ:MYMD) shares increased by 8.28% to $0.18. The company's market cap stands at $9.1 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 8.2% to $0.43. The market value of their outstanding shares is at $6.9 million. Windtree Therapeutics (NASDAQ:WINT) stock rose 6.12% to $0.47. The company's market cap stands at $3.0 million. BiomX (AMEX:PHGE) shares

Gainers Sagimet Biosciences (NASDAQ:SGMT) stock rose 103.5% to $13.88 during Monday's regular session. The company's market cap stands at $317.8 million. Bullfrog AI Hldgs (NASDAQ:BFRG) shares moved upwards by 41.1% to $6.9. The market value of their outstanding shares is at $42.0 million. Bone Biologics (NASDAQ:BBLG) shares increased by 32.3% to $4.3. The market value of their outstanding shares is at $2.2 million. 60 Degrees (NASDAQ:SXTP) stock moved upwards by 26.19% to $0.79. The company's market cap stands at $4.5 million. AquaBounty Techs (NASDAQ:AQB) stock rose 25.65% to $2.4. The company's market cap stands at $9.2 million. BIMI Intl Medical (NASDAQ:BIMI) shares increased by 22